858.277.5678
Quality Patient Care. Exceptional Research.
News & Resources

MARG News

Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5

Download PDF


Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C

Download PDF


ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients

View Press Release


Abbvie to present late-breaking results from TURQUOISE-II study in chronic hepatitis C patients with cirrhosis at the 2014 International Liver Congress

View Press Release


Gilead announces SVR12 rates from three phase III studies evaluating a once-daily fixeddose combination of sofosbuvir and ledipasvir for genotype 1 hepatitis C patients

Download the PDF


Abbvie demonstrates 96% SVR(12) in its phase III study of treatment-experienced patients with genotype 1 hepatitis C

Download the PDF


U.S. Food and Drug Administration approves Gilead’s Sovaldi™ (sofosbuvir) for the treatment of chronic hepatitis C

Download the PDF


Abbvie releases first of six phase III results from investigational all-oral, interferon-free, 12- week regimen, showing 96% SVR12 in genotype 1 hepatitis C patients new to therapy

Download the PDF


3-Drug Combo Halts HCV Infection

Download the PDF


Oral HCV Combos Promising

Download the PDF